- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00424411
Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes
February 9, 2007 updated by: Pfizer
Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial
To determine, in subjects with Type 2 Diabetes Mellitus:
- Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal EXUBERA™ (inhaled insulin) plus a single bedtime Ultralente injection as with a conventional subcutaneous insulin regimen involving 2 mixed Regular/NPH insulin injections per day.
- The toleration and safety of EXUBERA™ (inhaled insulin) therapy and its effects after 6 months, if any, on measures of pulmonary function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
300
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Pfizer Investigational Site
-
Edmonton, Alberta, Canada
- Pfizer Investigational Site
-
Red Deer, Alberta, Canada
- Pfizer Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Pfizer Investigational Site
-
-
Newfoundland and Labrador
-
St John's, Newfoundland and Labrador, Canada
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- Pfizer Investigational Site
-
-
Ontario
-
Mississauga, Ontario, Canada
- Pfizer Investigational Site
-
Ottawa, Ontario, Canada
- Pfizer Investigational Site
-
Toronto, Ontario, Canada
- Pfizer Investigational Site
-
-
Quebec
-
Chomedy, Quebec, Canada
- Pfizer Investigational Site
-
Montreal, Quebec, Canada
- Pfizer Investigational Site
-
-
-
-
California
-
Burlingame, California, United States
- Pfizer Investigational Site
-
Irvine, California, United States
- Pfizer Investigational Site
-
Los Angeles, California, United States
- Pfizer Investigational Site
-
Newport Beach, California, United States
- Pfizer Investigational Site
-
Orange, California, United States
- Pfizer Investigational Site
-
San Diego, California, United States
- Pfizer Investigational Site
-
San Francisco, California, United States
- Pfizer Investigational Site
-
Tustin, California, United States
- Pfizer Investigational Site
-
-
Connecticut
-
New Haven, Connecticut, United States
- Pfizer Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, United States
- Pfizer Investigational Site
-
-
Florida
-
Clearwater, Florida, United States
- Pfizer Investigational Site
-
Miami, Florida, United States
- Pfizer Investigational Site
-
Tampa, Florida, United States
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States
- Pfizer Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, United States
- Pfizer Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States
- Pfizer Investigational Site
-
-
Missouri
-
Columbia, Missouri, United States
- Pfizer Investigational Site
-
St Louis, Missouri, United States
- Pfizer Investigational Site
-
St. Louis, Missouri, United States
- Pfizer Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, United States
- Pfizer Investigational Site
-
-
New York
-
New Hyde Park, New York, United States
- Pfizer Investigational Site
-
New York, New York, United States
- Pfizer Investigational Site
-
Rochester, New York, United States
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, United States
- Pfizer Investigational Site
-
Greenville, North Carolina, United States
- Pfizer Investigational Site
-
Winston-salem, North Carolina, United States
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, United States
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, United States
- Pfizer Investigational Site
-
Dallas, Texas, United States
- Pfizer Investigational Site
-
Irving, Texas, United States
- Pfizer Investigational Site
-
San Antonio, Texas, United States
- Pfizer Investigational Site
-
-
Vermont
-
Burlington, Vermont, United States
- Pfizer Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, United States
- Pfizer Investigational Site
-
-
Washington
-
Renton, Washington, United States
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 Diabetes
- Stable insulin regimen of at least 2 injections per day
Exclusion Criteria:
- Any smoking within the last 6 months. Smoking is not permitted at any time during this study.
- Subjects on insulin pump during 2 months prior to screening.
- Subjects with poorly-controlled asthma, clinically significant chronic obstructive pulmonary disease, or other significant respiratory disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Primary outcome is 24 week change in baseline in HbA1c.
|
Secondary Outcome Measures
Outcome Measure |
---|
The secondary endpoints include the following efficacy assessments:
|
Incidence of hypoglycemia
|
Proportion of subjects with acceptable glycemic control (e.g., HbA1c<8%)
|
Change from baseline in fasting lipid profile
|
Change from baseline in fasting plasma glucose level
|
Change from baseline in meal glucose response (2-hour postprandial increment in plasma glucose)
|
Dose of insulin (total dose of injected sustained-duration insulin, and total dose of inhaled or injected Regular insulin during the study).
|
Change from baseline in body weight
|
Change from baseline in 24-hour home glucose profile (based on the area under the glucose profile curve calculated by the trapezoid rule with special weights assigned to the pre-breakfast and bedtime assessments).
|
Patient satisfaction and preference.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 1999
Study Completion
December 1, 2000
Study Registration Dates
First Submitted
January 17, 2007
First Submitted That Met QC Criteria
January 17, 2007
First Posted (Estimate)
January 19, 2007
Study Record Updates
Last Update Posted (Estimate)
February 13, 2007
Last Update Submitted That Met QC Criteria
February 9, 2007
Last Verified
February 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 217-108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on Inhaled human insulin (EXUBERA™)
-
PfizerTerminated
-
PfizerTerminatedDiabetes Mellitus, Type 2Singapore, Hong Kong, Philippines, Pakistan
-
PfizerCompletedDiabetes Mellitus, Type 2United States
-
PfizerTerminatedDiabetes Mellitus, Type 1Denmark, Spain, Sweden, United States, Belgium, Austria, France, Portugal, Ireland, United Kingdom, Finland, Netherlands, Norway
-
PfizerCompletedDiabetes Mellitus, Type 2Germany, Netherlands, Sweden, Poland, Belgium, Finland, France, Norway, Spain, Switzerland
-
PfizerTerminatedDiabetes MellitusCanada, United States, Brazil, Puerto Rico
-
PfizerTerminatedDiabetes Mellitus Type 2Spain, Canada, France, Greece, Portugal, Sweden, Turkey
-
PfizerCompletedDiabetes Mellitus, Type 2United States, Puerto Rico
-
PfizerTerminatedDiabetes Mellitus, Type 1United States
-
PfizerCompletedDiabetes MellitusUnited States, Germany, Sweden, United Kingdom, Puerto Rico